crusia (enoxaparina sódica) solucion inyectable s.c., i.v., linea arterial (hemodialisis).en jeringa prellenada
laboratorios farmacÉuticos rovi, s.a. - enoxaparina sÓdica - enoxaparina sÓdica....100 mg/ml
lovenox- enoxaparin sodium injection
physicians total care, inc. - enoxaparin sodium (unii: 8nz41mik1o) (enoxaparin - unii:e47c0nf7lv) - enoxaparin sodium 40 mg in 0.4 ml - lovenox® is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): - in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see clinical studies (14.1) ]. - in patients undergoing hip replacement surgery, during and following hospitalization. - in patients undergoing knee replacement surgery. - in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness. lovenox is indicated for: - the inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium. - the outpatient treatment of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with warfarin sodium. lovenox is indicated for the prophylaxis of ischemic complications of unstable angina and non-q-wave myocardial infarction, when concurrently administered with aspirin. lovenox, when administered con
lovenox enoxaparin sodium injection
cardinal health - enoxaparin sodium (unii: 8nz41mik1o) (enoxaparin - unii:e47c0nf7lv) - enoxaparin sodium 30 mg in 0.3 ml
lovenox- enoxaparin sodium injection
sanofi-aventis u.s. llc - enoxaparin sodium (unii: 8nz41mik1o) (enoxaparin - unii:e47c0nf7lv) - enoxaparin sodium 30 mg in 0.3 ml - lovenox® is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): - in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see clinical studies (14.1)] - in patients undergoing hip replacement surgery, during and following hospitalization - in patients undergoing knee replacement surgery - in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness lovenox is indicated for: - the inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism , when administered in conjunction with warfarin sodium - the outpatient treatment of acute deep vein thrombosis without pulmonary embolism , when administered in conjunction with warfarin sodium lovenox is indicated for the prophylaxis of ischemic complications of unstable angina and non–q-wave myocardial infarction, when concurrently administered with aspirin. lovenox, when administered concurren
clexane forte enoxaparin sodium 150mg/1ml injection syringe
sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 150 mg - injection, solution - excipient ingredients: nitrogen; water for injections - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
clexane forte enoxaparin sodium 120mg/0.8ml injection syringe
sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 120 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
clexane enoxaparin sodium 100mg/1ml injection syringe
sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
clexane enoxaparin sodium 80mg/0.8ml injection syringe
sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 80 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
clexane enoxaparin sodium 60mg/0.6ml injection syringe
sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 60 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
clexane enoxaparin sodium 20mg/0.2ml injection syringe
sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 20 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).